Cell Cycle Inhibitors Market, Global Outlook and Forecast 2022-2028

April 2022 | 102 pages | ID: C727E92260B1EN
Market Monitor Global

Abstracts

Cell cycle inhibitors basically interrupt the growth proteins in order to slow or even stop the progression of the cell cycle. Cell cycle arrest can be induced at any point during the cell cycle, slowing cell division and reducing the number of actively cycling cells. The cell cycle inhibitors aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body and generally make the process slower or completely stop the cell division.

This report contains market size and forecasts of Cell Cycle Inhibitors in Global, including the following market information:

Global Cell Cycle Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Cell Cycle Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

CDK4 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cell Cycle Inhibitors include Sanofi, Syros Pharmaceuticals, Piramal Enterprises, Pfizer, NMS Group, G1 Therapeutics, Eli Lilly and Company, Cyclacel Pharmaceuticals and F. Hoffmann-La Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cell Cycle Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cell Cycle Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Cell Cycle Inhibitors Market Segment Percentages, by Type, 2021 (%)

• CDK4 Inhibitors
• CDK9 Inhibitors
• CDK6 Inhibitors
• Others

Global Cell Cycle Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Cell Cycle Inhibitors Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Specialty Clinics
• Others

Global Cell Cycle Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Cell Cycle Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cell Cycle Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Cell Cycle Inhibitors revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi
• Syros Pharmaceuticals
• Piramal Enterprises
• Pfizer
• NMS Group
• G1 Therapeutics
• Eli Lilly and Company
• Cyclacel Pharmaceuticals
• F. Hoffmann-La Roche
• Regeneron Pharmaceuticals
• Teva Pharmaceuticals Industries
• Sanofi
• Genentech
• Sanofi Regeneron Pharmaceuticals
• BioCAD GLOBAL
• Bayer AG
• Otsuka America
• Amgen
• ANYGEN

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Cell Cycle Inhibitors Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Cell Cycle Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CELL CYCLE INHIBITORS OVERALL MARKET SIZE

2.1 Global Cell Cycle Inhibitors Market Size: 2021 VS 2028
2.2 Global Cell Cycle Inhibitors Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Cell Cycle Inhibitors Players in Global Market
3.2 Top Global Cell Cycle Inhibitors Companies Ranked by Revenue
3.3 Global Cell Cycle Inhibitors Revenue by Companies
3.4 Top 3 and Top 5 Cell Cycle Inhibitors Companies in Global Market, by Revenue in 2021
3.5 Global Companies Cell Cycle Inhibitors Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cell Cycle Inhibitors Players in Global Market
  3.6.1 List of Global Tier 1 Cell Cycle Inhibitors Companies
  3.6.2 List of Global Tier 2 and Tier 3 Cell Cycle Inhibitors Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Cell Cycle Inhibitors Market Size Markets, 2021 & 2028
  4.1.2 CDK4 Inhibitors
  4.1.3 CDK9 Inhibitors
  4.1.4 CDK6 Inhibitors
  4.1.5 Others
4.2 By Type - Global Cell Cycle Inhibitors Revenue & Forecasts
  4.2.1 By Type - Global Cell Cycle Inhibitors Revenue, 2017-2022
  4.2.2 By Type - Global Cell Cycle Inhibitors Revenue, 2023-2028
  4.2.3 By Type - Global Cell Cycle Inhibitors Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Cell Cycle Inhibitors Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Specialty Clinics
  5.1.4 Others
5.2 By Application - Global Cell Cycle Inhibitors Revenue & Forecasts
  5.2.1 By Application - Global Cell Cycle Inhibitors Revenue, 2017-2022
  5.2.2 By Application - Global Cell Cycle Inhibitors Revenue, 2023-2028
  5.2.3 By Application - Global Cell Cycle Inhibitors Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Cell Cycle Inhibitors Market Size, 2021 & 2028
6.2 By Region - Global Cell Cycle Inhibitors Revenue & Forecasts
  6.2.1 By Region - Global Cell Cycle Inhibitors Revenue, 2017-2022
  6.2.2 By Region - Global Cell Cycle Inhibitors Revenue, 2023-2028
  6.2.3 By Region - Global Cell Cycle Inhibitors Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Cell Cycle Inhibitors Revenue, 2017-2028
  6.3.2 US Cell Cycle Inhibitors Market Size, 2017-2028
  6.3.3 Canada Cell Cycle Inhibitors Market Size, 2017-2028
  6.3.4 Mexico Cell Cycle Inhibitors Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Cell Cycle Inhibitors Revenue, 2017-2028
  6.4.2 Germany Cell Cycle Inhibitors Market Size, 2017-2028
  6.4.3 France Cell Cycle Inhibitors Market Size, 2017-2028
  6.4.4 U.K. Cell Cycle Inhibitors Market Size, 2017-2028
  6.4.5 Italy Cell Cycle Inhibitors Market Size, 2017-2028
  6.4.6 Russia Cell Cycle Inhibitors Market Size, 2017-2028
  6.4.7 Nordic Countries Cell Cycle Inhibitors Market Size, 2017-2028
  6.4.8 Benelux Cell Cycle Inhibitors Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Cell Cycle Inhibitors Revenue, 2017-2028
  6.5.2 China Cell Cycle Inhibitors Market Size, 2017-2028
  6.5.3 Japan Cell Cycle Inhibitors Market Size, 2017-2028
  6.5.4 South Korea Cell Cycle Inhibitors Market Size, 2017-2028
  6.5.5 Southeast Asia Cell Cycle Inhibitors Market Size, 2017-2028
  6.5.6 India Cell Cycle Inhibitors Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Cell Cycle Inhibitors Revenue, 2017-2028
  6.6.2 Brazil Cell Cycle Inhibitors Market Size, 2017-2028
  6.6.3 Argentina Cell Cycle Inhibitors Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Cell Cycle Inhibitors Revenue, 2017-2028
  6.7.2 Turkey Cell Cycle Inhibitors Market Size, 2017-2028
  6.7.3 Israel Cell Cycle Inhibitors Market Size, 2017-2028
  6.7.4 Saudi Arabia Cell Cycle Inhibitors Market Size, 2017-2028
  6.7.5 UAE Cell Cycle Inhibitors Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Sanofi
  7.1.1 Sanofi Corporate Summary
  7.1.2 Sanofi Business Overview
  7.1.3 Sanofi Cell Cycle Inhibitors Major Product Offerings
  7.1.4 Sanofi Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.1.5 Sanofi Key News
7.2 Syros Pharmaceuticals
  7.2.1 Syros Pharmaceuticals Corporate Summary
  7.2.2 Syros Pharmaceuticals Business Overview
  7.2.3 Syros Pharmaceuticals Cell Cycle Inhibitors Major Product Offerings
  7.2.4 Syros Pharmaceuticals Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.2.5 Syros Pharmaceuticals Key News
7.3 Piramal Enterprises
  7.3.1 Piramal Enterprises Corporate Summary
  7.3.2 Piramal Enterprises Business Overview
  7.3.3 Piramal Enterprises Cell Cycle Inhibitors Major Product Offerings
  7.3.4 Piramal Enterprises Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.3.5 Piramal Enterprises Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Cell Cycle Inhibitors Major Product Offerings
  7.4.4 Pfizer Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.4.5 Pfizer Key News
7.5 NMS Group
  7.5.1 NMS Group Corporate Summary
  7.5.2 NMS Group Business Overview
  7.5.3 NMS Group Cell Cycle Inhibitors Major Product Offerings
  7.5.4 NMS Group Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.5.5 NMS Group Key News
7.6 G1 Therapeutics
  7.6.1 G1 Therapeutics Corporate Summary
  7.6.2 G1 Therapeutics Business Overview
  7.6.3 G1 Therapeutics Cell Cycle Inhibitors Major Product Offerings
  7.6.4 G1 Therapeutics Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.6.5 G1 Therapeutics Key News
7.7 Eli Lilly and Company
  7.7.1 Eli Lilly and Company Corporate Summary
  7.7.2 Eli Lilly and Company Business Overview
  7.7.3 Eli Lilly and Company Cell Cycle Inhibitors Major Product Offerings
  7.7.4 Eli Lilly and Company Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.7.5 Eli Lilly and Company Key News
7.8 Cyclacel Pharmaceuticals
  7.8.1 Cyclacel Pharmaceuticals Corporate Summary
  7.8.2 Cyclacel Pharmaceuticals Business Overview
  7.8.3 Cyclacel Pharmaceuticals Cell Cycle Inhibitors Major Product Offerings
  7.8.4 Cyclacel Pharmaceuticals Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.8.5 Cyclacel Pharmaceuticals Key News
7.9 F. Hoffmann-La Roche
  7.9.1 F. Hoffmann-La Roche Corporate Summary
  7.9.2 F. Hoffmann-La Roche Business Overview
  7.9.3 F. Hoffmann-La Roche Cell Cycle Inhibitors Major Product Offerings
  7.9.4 F. Hoffmann-La Roche Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.9.5 F. Hoffmann-La Roche Key News
7.10 Regeneron Pharmaceuticals
  7.10.1 Regeneron Pharmaceuticals Corporate Summary
  7.10.2 Regeneron Pharmaceuticals Business Overview
  7.10.3 Regeneron Pharmaceuticals Cell Cycle Inhibitors Major Product Offerings
  7.10.4 Regeneron Pharmaceuticals Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.10.5 Regeneron Pharmaceuticals Key News
7.11 Teva Pharmaceuticals Industries
  7.11.1 Teva Pharmaceuticals Industries Corporate Summary
  7.11.2 Teva Pharmaceuticals Industries Business Overview
  7.11.3 Teva Pharmaceuticals Industries Cell Cycle Inhibitors Major Product Offerings
  7.11.4 Teva Pharmaceuticals Industries Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.11.5 Teva Pharmaceuticals Industries Key News
7.12 Sanofi
  7.12.1 Sanofi Corporate Summary
  7.12.2 Sanofi Business Overview
  7.12.3 Sanofi Cell Cycle Inhibitors Major Product Offerings
  7.12.4 Sanofi Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.12.5 Sanofi Key News
7.13 Genentech
  7.13.1 Genentech Corporate Summary
  7.13.2 Genentech Business Overview
  7.13.3 Genentech Cell Cycle Inhibitors Major Product Offerings
  7.13.4 Genentech Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.13.5 Genentech Key News
7.14 Sanofi Regeneron Pharmaceuticals
  7.14.1 Sanofi Regeneron Pharmaceuticals Corporate Summary
  7.14.2 Sanofi Regeneron Pharmaceuticals Business Overview
  7.14.3 Sanofi Regeneron Pharmaceuticals Cell Cycle Inhibitors Major Product Offerings
  7.14.4 Sanofi Regeneron Pharmaceuticals Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.14.5 Sanofi Regeneron Pharmaceuticals Key News
7.15 BioCAD GLOBAL
  7.15.1 BioCAD GLOBAL Corporate Summary
  7.15.2 BioCAD GLOBAL Business Overview
  7.15.3 BioCAD GLOBAL Cell Cycle Inhibitors Major Product Offerings
  7.15.4 BioCAD GLOBAL Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.15.5 BioCAD GLOBAL Key News
7.16 Bayer AG
  7.16.1 Bayer AG Corporate Summary
  7.16.2 Bayer AG Business Overview
  7.16.3 Bayer AG Cell Cycle Inhibitors Major Product Offerings
  7.16.4 Bayer AG Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.16.5 Bayer AG Key News
7.17 Otsuka America
  7.17.1 Otsuka America Corporate Summary
  7.17.2 Otsuka America Business Overview
  7.17.3 Otsuka America Cell Cycle Inhibitors Major Product Offerings
  7.17.4 Otsuka America Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.17.5 Otsuka America Key News
7.18 Amgen
  7.18.1 Amgen Corporate Summary
  7.18.2 Amgen Business Overview
  7.18.3 Amgen Cell Cycle Inhibitors Major Product Offerings
  7.18.4 Amgen Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.18.5 Amgen Key News
7.19 ANYGEN
  7.19.1 ANYGEN Corporate Summary
  7.19.2 ANYGEN Business Overview
  7.19.3 ANYGEN Cell Cycle Inhibitors Major Product Offerings
  7.19.4 ANYGEN Cell Cycle Inhibitors Revenue in Global Market (2017-2022)
  7.19.5 ANYGEN Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Cell Cycle Inhibitors Market Opportunities & Trends in Global Market
Table 2. Cell Cycle Inhibitors Market Drivers in Global Market
Table 3. Cell Cycle Inhibitors Market Restraints in Global Market
Table 4. Key Players of Cell Cycle Inhibitors in Global Market
Table 5. Top Cell Cycle Inhibitors Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Cell Cycle Inhibitors Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Cell Cycle Inhibitors Revenue Share by Companies, 2017-2022
Table 8. Global Companies Cell Cycle Inhibitors Product Type
Table 9. List of Global Tier 1 Cell Cycle Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cell Cycle Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Cell Cycle Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Cell Cycle Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Cell Cycle Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Cell Cycle Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Cell Cycle Inhibitors Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Cell Cycle Inhibitors Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Cell Cycle Inhibitors Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Cell Cycle Inhibitors Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Cell Cycle Inhibitors Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Cell Cycle Inhibitors Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Cell Cycle Inhibitors Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Cell Cycle Inhibitors Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Cell Cycle Inhibitors Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Cell Cycle Inhibitors Revenue, (US$, Mn), 2023-2028
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Cell Cycle Inhibitors Product Offerings
Table 32. Sanofi Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 33. Syros Pharmaceuticals Corporate Summary
Table 34. Syros Pharmaceuticals Cell Cycle Inhibitors Product Offerings
Table 35. Syros Pharmaceuticals Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 36. Piramal Enterprises Corporate Summary
Table 37. Piramal Enterprises Cell Cycle Inhibitors Product Offerings
Table 38. Piramal Enterprises Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Cell Cycle Inhibitors Product Offerings
Table 41. Pfizer Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 42. NMS Group Corporate Summary
Table 43. NMS Group Cell Cycle Inhibitors Product Offerings
Table 44. NMS Group Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 45. G1 Therapeutics Corporate Summary
Table 46. G1 Therapeutics Cell Cycle Inhibitors Product Offerings
Table 47. G1 Therapeutics Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 48. Eli Lilly and Company Corporate Summary
Table 49. Eli Lilly and Company Cell Cycle Inhibitors Product Offerings
Table 50. Eli Lilly and Company Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 51. Cyclacel Pharmaceuticals Corporate Summary
Table 52. Cyclacel Pharmaceuticals Cell Cycle Inhibitors Product Offerings
Table 53. Cyclacel Pharmaceuticals Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 54. F. Hoffmann-La Roche Corporate Summary
Table 55. F. Hoffmann-La Roche Cell Cycle Inhibitors Product Offerings
Table 56. F. Hoffmann-La Roche Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 57. Regeneron Pharmaceuticals Corporate Summary
Table 58. Regeneron Pharmaceuticals Cell Cycle Inhibitors Product Offerings
Table 59. Regeneron Pharmaceuticals Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 60. Teva Pharmaceuticals Industries Corporate Summary
Table 61. Teva Pharmaceuticals Industries Cell Cycle Inhibitors Product Offerings
Table 62. Teva Pharmaceuticals Industries Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 63. Sanofi Corporate Summary
Table 64. Sanofi Cell Cycle Inhibitors Product Offerings
Table 65. Sanofi Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 66. Genentech Corporate Summary
Table 67. Genentech Cell Cycle Inhibitors Product Offerings
Table 68. Genentech Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 69. Sanofi Regeneron Pharmaceuticals Corporate Summary
Table 70. Sanofi Regeneron Pharmaceuticals Cell Cycle Inhibitors Product Offerings
Table 71. Sanofi Regeneron Pharmaceuticals Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 72. BioCAD GLOBAL Corporate Summary
Table 73. BioCAD GLOBAL Cell Cycle Inhibitors Product Offerings
Table 74. BioCAD GLOBAL Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 75. Bayer AG Corporate Summary
Table 76. Bayer AG Cell Cycle Inhibitors Product Offerings
Table 77. Bayer AG Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 78. Otsuka America Corporate Summary
Table 79. Otsuka America Cell Cycle Inhibitors Product Offerings
Table 80. Otsuka America Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 81. Amgen Corporate Summary
Table 82. Amgen Cell Cycle Inhibitors Product Offerings
Table 83. Amgen Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)
Table 84. ANYGEN Corporate Summary
Table 85. ANYGEN Cell Cycle Inhibitors Product Offerings
Table 86. ANYGEN Cell Cycle Inhibitors Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Cell Cycle Inhibitors Segment by Type in 2021
Figure 2. Cell Cycle Inhibitors Segment by Application in 2021
Figure 3. Global Cell Cycle Inhibitors Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Cell Cycle Inhibitors Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cell Cycle Inhibitors Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cell Cycle Inhibitors Revenue in 2021
Figure 8. By Type - Global Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 9. By Application - Global Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 10. By Region - Global Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 11. By Country - North America Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 12. US Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 16. Germany Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 17. France Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 24. China Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 28. India Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 30. Brazil Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Cell Cycle Inhibitors Revenue Market Share, 2017-2028
Figure 33. Turkey Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Cell Cycle Inhibitors Revenue, (US$, Mn), 2017-2028
Figure 37. Sanofi Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Syros Pharmaceuticals Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Piramal Enterprises Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. NMS Group Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. G1 Therapeutics Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Eli Lilly and Company Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Cyclacel Pharmaceuticals Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. F. Hoffmann-La Roche Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Regeneron Pharmaceuticals Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Teva Pharmaceuticals Industries Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Sanofi Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Genentech Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Sanofi Regeneron Pharmaceuticals Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. BioCAD GLOBAL Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Bayer AG Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Otsuka America Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Amgen Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. ANYGEN Cell Cycle Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)